Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292422 · ClinicalTrials.gov registry record · Phase 2
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00292422 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 50 participants.
The verdict
NCT00292422, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This Phase 2a study is designed to evaluate the safety and tolerability of multiple subcutaneous (SC) doses of BG9924, administered in a cohort dose-escalation fashion, in patients with active rheumatoid arthritis (RA) who have had an inadequate response to therapy with disease-modifying anti rheumatic drugs (DMARDs) and who may have undergone anti-TNF therapy. This study will assist with dose selection for further planned Phase 2 studies.
Interventions
- DRUG BG9924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00292422
The ClinicalTrials.gov registry entry for NCT00292422 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BG9924 is the first listed.
NCT00292422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00292422 about?
NCT00292422 is a clinical study titled "Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis". This Phase 2a study is designed to evaluate the safety and tolerability of multiple subcutaneous (SC) doses of BG9924, administered in a cohort dose-escalation fashion, in patients with active rheumatoid arthritis (RA) who have had an inadequate response to therapy with disease-modifying anti rheuma...
What is the current status of trial NCT00292422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-11. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00292422?
The interventions under investigation include: BG9924 (DRUG).
Who is sponsoring clinical trial NCT00292422?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.